Caveat oncologist: Clinical findings and consequences of distributing counterfeit erythropoietin in the United States

Journal of Oncology Practice

Volumn 8, Issue 2, 2012, Pages 84-90

  Qureshi, Zaina P ^a,b,c,d,e,f   Norris, LeAnn ^a,b,c,d,e,f   Sartor, Oliver ^a,b,c,d,e,f   McKoy, June M ^a,b,c,d,e,f   Armstrong, John ^a,b,c,d,e,f   Raisch, Dennis W ^a,b,c,d,e,f   Garg, Vishvas ^a,b,c,d,e,f   Stafkey Mailey, Dana ^a,b,c,d,e,f   Bennett, Charles Lee ^a,b,c,d,e,f  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e University of New Mexico   (United States)

^f Lead Horse Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COUNTERFEIT DRUG; ERYTHROPOIETIN;

ARTICLE; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TRAFFIC; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERVIEW; LAWYER; PHYSICIAN; UNITED STATES;

EID: 84865452198     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000325     Document Type: Article

References (25)

1. US Food and Drug Administration: Counterfeit Medicine. http://www.fda.gov/oc/initiatives/counterfeit/qa.html
2. Federal Food, Drug and Cosmetic Act. U.S.C. §201(g)(2), 2004
3. Rudolf PM, Bernstein IB: Counterfeit drugs. N Engl J Med 350:1384-1386, 2004 (Pubitemid 38419991)
4. National Association of Boards of Pharmacy: National Specified List of Susceptible Products. http://www.state.nj.us/health/eoh/slsdp.pdf
5. Eban K: Dangerous Doses: How Counterfeiters Are Contaminating America's Drug Supply. New York, NY, Harcourt, 2005
6. deKieffer D: Potential liability for counterfeit medications. J Pharm Pract 19:215-220, 2006
7. ASHP congressional testimony on the "gray market" in pharmaceuticals. Am J Hosp Pharm 43:426-429, 1986
8. Prescription Drug Marketing Act of 1987, Public Law No. 100-293, 102 Stat. 95, 1987
9. Amendments of Prescription Drug Marketing Act of 21 CFR §§203.3, (u) and 203.50, 2006
10. Food and Drug Cosmetic Act of Pubic Law No 52 Stat. 1040:75-717, 1938
11. Lanham Trademark Act of U.S.C. §1051-1128, 1946
12. Draft Compliance Guide. Prescription Drug Marketing Act- Pedigree Requirements under 21 CFR Part 203. June 16, 2006. http://www.fda.gov/oc/ initiatives/counterfeit/cpg.html
13. Trademark Dilution Review Act of Public Law 109-312, 2006
14. Better Living Through Technology. TMIS Newsletter. Orting, WV, TM Information Systems. http://www.tmis.org/enewsletters/2010-7-20.html
15. US Food and Drug Administration: MedWatch Safety Alerts for Human Medical Products. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/default.htm
16. US Food and Drug Administration: Procrit (epoetin alfa) Dear Healthcare Professional Letter Mar 2003. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm167374.htm
17. US Food and Drug Administration: Counterfeit Drug Task Force Report October 2003 - THE COUNTERFEIT DRUG TASK FORCE. http://www.fda.gov/Drugs/ DrugSafety/ucm174399.htm
18. US Food and Drug Administration: Counterfeit Drug Taskforce: Counterfeit Drug Task Force Report: February 2004 COMBATING COUNTERFEIT DRUGS. http://www.fda.gov/Drugs/DrugSafety/ucm173231.htm
19. US Food and Drug Administration: Counterfeit Drug Task Force Report: May 2005. Combating Counterfeit Drugs: A Report of the Food and Drug Administration Annual Update. http://www.fda.gov/Drugs/DrugSafety/ucm172935.htm
20. US Food and Drug Administration: Counterfeit Drug Task Force Report: June 2006. http://www.fda.gov/Drugs/DrugSafety/ucm172759.htm
21. US Food and Drug Administration: Counterfeit Alert Network. http://www.fda.gov/Drugs/DrugSafety/ucm170315.htm
22. Ling L: While we are waiting: Imagining and creating a safe drug supply while we await the coming of the radio frequency identification track-and-trace system. J Pharm Pract 19:153-160, 2006
23. CardinalLatestWholesalertoCurbSecondaryDealing.http://www.findarticles. com/p/articles/mi-m3374/is-7-27/ai-n13788235
24. Blossom D, Kallen A, Patel P, et al: Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 359:2674-2684, 2008
25. Combating counterfeit drugs. Lancet 371:1551, 2008